Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485680 | 0.93 | CXCR2 (0.52) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL485257 | 0.83 | EPHX2 (0.45) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL28768791 | 0.82 | NPC1 (0.41) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL484358 | 0.80 | CXCR2 (0.56) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL485628 | 0.80 | CXCR2 (0.58) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL3934327 | 0.79 | CXCR2 (0.50) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL485408 | 0.78 | NPC1 (0.46) | CXCR2NPC1ALOX5EPHX2RAB9A | |
| SCHEMBL486121 | 0.78 | MAOB (0.47) | NPC1ALOX5EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL3930274 | 0.78 | CXCR2 (0.80) | CXCR2 | |
| SCHEMBL485445 | 0.77 | NPC1 (0.46) | CXCR2NPC1ALOX5EPHX2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | claimed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | claimed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | claimed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | claimed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215827-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885NPC1 1229/4885ALOX5 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.